Fortress Biotech Inc 9.375% Series A Cumulativ (FBIOP)

$5.68 -0.07 (-1.26%)
Market Cap N/A
Revenue (ttm) 84.51M
Net Income (ttm) -60.64M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 304
Avg Vol 18,892
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 79%
Beta N/A
Analysts Strong Buy
Price Target N/A

Latest News on FBIOP

Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics

May 30, 2025, 10:47 AM EDT - 8 days ago

Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics

FBIO

Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 15, 2025, 4:05 PM EDT - 23 days ago

Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

FBIO

Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference

May 7, 2025, 8:00 AM EDT - 4 weeks ago

Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference

FBIO

Fortress Biotech, Inc. (FBIO) Q4 2024 Earnings Call Transcript

Mar 26, 2025, 7:39 PM EDT - 2 months ago

Fortress Biotech, Inc. (FBIO) Q4 2024 Earnings Call Transcript

FBIO

Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform

Mar 17, 2025, 8:55 AM EDT - 2 months ago

Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform

FBIO

Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT

Jan 27, 2025, 8:30 AM EST - 4 months ago

Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT

FBIO

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease

Jan 6, 2025, 8:00 AM EST - 5 months ago

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease

FBIO

Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Nov 14, 2024, 4:10 PM EST - 7 months ago

Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

FBIO

Fortress Biotech to Participate in October 2024 Investor Conferences

Sep 26, 2024, 8:30 AM EDT - 9 months ago

Fortress Biotech to Participate in October 2024 Investor Conferences

FBIO

Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements

Sep 20, 2024, 8:30 AM EDT - 9 months ago

Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements

FBIO

Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 8:30 AM EDT - 9 months ago

Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference

FBIO

Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Aug 13, 2024, 4:05 PM EDT - 10 months ago

Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

FBIO

Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027

Jul 25, 2024, 8:30 AM EDT - 11 months ago

Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027

FBIO

Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Jul 5, 2024, 4:05 PM EDT - 1 year ago

Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

FBIO

Fortress Biotech, Inc. (FBIO) Q3 2022 Earnings Call Transcript

Nov 10, 2022, 10:42 PM EST - 2 years ago

Fortress Biotech, Inc. (FBIO) Q3 2022 Earnings Call Transcript

FBIO

Journey Medical Corporation (FBIO) CEO Claude Maraoui on Q2 2022 Results - Earnings Call Transcript

Aug 9, 2022, 9:05 PM EDT - 3 years ago

Journey Medical Corporation (FBIO) CEO Claude Maraoui on Q2 2022 Results - Earnings Call Transcript

FBIO

Plenty Of Further Upside In Fortress Biotech

Mar 19, 2019, 12:01 PM EDT - 6 years ago

Plenty Of Further Upside In Fortress Biotech

FBIO